Trump says Eli Lilly plans six new US manufacturing plants

President Donald Trump said on January 29, 2026 that Eli Lilly plans to build six new manufacturing plants in the United States, according to a Reuters report ^[1]. The remark expands on a U.S. production program Lilly had already announced.

Lilly has said it would invest at least $27 billion to expand production and strengthen medical supply chains ^[1]. Under that earlier plan, the company described four plants, with three sites already confirmed, in Alabama, Virginia, and Texas ^[1]. Lilly has said the expansion is meant to boost U.S. manufacturing capacity and support its long-term growth in pharmaceuticals ^[1].

It has not been reported whether the six plants the President described include those four sites or come on top of them. The locations, costs, and construction schedules for any additional plants have not been disclosed, and Lilly has not said which medicines they would make.

Lilly discovers, develops, manufactures, and markets medicines, with work in diabetes, oncology, immunology, neurodegeneration, and pain ^[1]. Demand for its GLP-1 medicines, including Mounjaro, has been a major source of its growth, and analysts cited in the same report expect the company to benefit from its push to expand diabetes treatment ^[1]. The plant program is separate from the company's drug approvals and does not change any medicine that is already on the market.

Why it matters for patients

Where a medicine is manufactured does not change what the medicine is or how it is used. What more U.S. plants could affect, over time, is how much product Lilly is able to make. But no timeline was given, so any effect on the supply of Lilly medicines would not be immediate, and it is not known whether the new capacity is intended for any particular drug.

The $27 billion figure is an investment amount, not a price. Nothing in the report indicates changes to the price of any Lilly medicine, to insurance coverage, or to how medicines are prescribed. Those topics have not been reported in connection with the plant announcement.

For people already taking a Lilly medicine, the news describes construction plans rather than changes to products. Whether the plants would make injectable GLP-1 medicines, oral medicines, or other products has not been disclosed.

What happens next

The only date attached to the six-plant figure is January 29, 2026, when the President made the remark ^[1]. The earlier four-plant program comes from Lilly's prior announcements, which listed Alabama, Virginia, and Texas as confirmed sites ^[1].

The missing pieces include a company confirmation of the six-plant figure, the states or cities involved, how much any additional plants would cost, and when construction or production would begin. Lilly has not announced a schedule for the plants described by the President, and no completion dates have been reported.